Genmab A/S (0MGB.L)

2.581,26 -9,88 (-0,38%) Alla chiusura: 06:18PM BST

Genmab A/S

Carl Jacobsens Vej 30
Valby
Copenhagen 2500
Denmark
45 70 20 27 28
https://www.genmab.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 2.204

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Jan G.J. van de Winkel Ph.D.	Co-Founder, President & CEO	20M	N/D	1961
Mr. Anthony Pagano	Executive VP & CFO	7,1M	N/D	1978
Ms. Birgitte Stephensen M.Sc.	Executive VP & Chief Legal Officer	4,4M	N/D	1961
Dr. Martine J. van Vugt Ph.D.	Executive VP & Chief Strategy Officer	4,8M	N/D	1971
Mr. Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	800k	N/D	1976
Dr. Tahamtan Ahmadi	Executive VP, Chief Medical Officer & Head of Experimental Medicines	7,7M	N/D	1973
Dr. Mijke Zachariasse Ph.D.	Senior Director, Head of Antibody Research Materials & Non-Independent Director	1,1M	N/D	1974
Mr. Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	800k	N/D	1975
Mr. Anthony Mancini	Executive VP & COO	7,6M	N/D	1971
Mr. Andrew Carlsen	Senior Director, VP & Head of Investor Relations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in DKK.

Descrizione

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Governance aziendale

L'ISS Governance QualityScore di Genmab A/S al 1 aprile 2024 è 3. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 1; diritti degli azionisti: 1; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.